Format

Send to

Choose Destination
Eur J Surg Oncol. 2019 Jan;45(1):40-45. doi: 10.1016/j.ejso.2018.02.007. Epub 2018 Feb 14.

Treatment challenges in and outside a network setting: Head and neck cancers.

Collaborators (118)

Hackl M6, Eycken EV7, Henau K7, Dimitrova N8, Sekerija M9, Dušek L10, Mägi M11, Malila N12, Leinonen M12, Velten M13, Troussard X14, Bouvier V15, Guizard AV16, Bouvier AM17, Arveux P18, Maynadié M19, Woronoff AS20, Robaszkiewic M21, Baldi I22, Monnereau A23, Tretarre B24, Colonna M25, Molinié F26, Bara S27, Schvartz C28, Lapôtre-Ledoux B29, Grosclaude P30, Stabenow R31, Luttmann S32, Nennecke A33, Engel J34, Schubert-Fritschle G34, Heidrich J35, Holleczek B36, Jónasson JG37, Clough-Gorr K38, Comber H38, Mazzoleni G39, Giacomin A40, Sutera Sardo A41, Barchielli A42, Serraino D43, De Angelis R44, Mallone S44, Tavilla A44, Pierannunzio D44, Rossi S44, Santaquilani M44, Knijn A44, Pannozzo F45, Gennaro V46, Benfatto L46, Ricci P47, Autelitano M48, Spagnoli G49, Fusco M50, Usala M51, Vitale F52, Michiara M53, Tumino R54, Mangone L55, Falcini F56, Ferretti S57, Filiberti RA58, Marani E58, Iannelli A59, Sensi F60, Piffer S61, Gentilini M61, Madeddu A62, Ziino A62, Maspero S63, Candela P64, Stracci F65, Tagliabue G66, Rugge M67, Trama A68, Gatta G68, Botta L68, Capocaccia R68, Pildava S69, Smailyte G70, Calleja N71, Johannesen TB72, Rachtan J73, Góźdź S74, Błaszczyk J75, Kępska K75, de Lacerda GF76, Bento MJ77, Miranda A78, Diba CS79, Almar E80, Larrañaga N81, de Munain AL81, Torrella-Ramos A82, Díaz García JM83, Marcos-Gragera R84, Sanchez MJ85, Navarro C86, Salmeron D86, Moreno-Iribas C87, Galceran J88, Carulla M88, Mousavi M89, Bouchardy C90, Ess SM91, Bordoni A92, Konzelmann I93, Rashbass J94, Gavin A95, Brewster DH96, Huws DW97, Visser O98, Bielska-Lasota M99, Primic-Zakelj M100, Kunkler I101, Benhamou E102.

Author information

1
Radiotherapy 2 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: ester.orlandi@istitutotumori.mi.it.
2
Medical Oncology 3 Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
3
Department of Otolaryngology Head and Neck Surgery, CHUV University of Lausanne, Switzerland.
4
Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
5
Medical Oncology 3 Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; University of Milan, Italy.
6
Austrian National Cancer Registry, Austria.
7
Belgian Cancer Registry, Belgium.
8
Bulgaria Cancer Registry, Bulgaria; Bulgarian Cancer Registry, Bulgaria.
9
Croatian Cancer Registry, Croatia.
10
Czech National Cancer Registry, Czech Republic.
11
Estonian Cancer Registry, Estonia.
12
Finnish Cancer Registry, Finland.
13
Bas Rhin Cancer Registry, France.
14
Basse Normandie Haematological malignancies Registry, France.
15
Calvados Digestive Tract Registry, France.
16
Calvados, Registre Gèneral des Tumeurs, France.
17
Côte d'Or Digestive Tract Registry, Burgundy, France.
18
Côte d'Or Gynaecologic Cancer registry, France.
19
Côte d'Or Haematological Malignancies Cancer Registry, France.
20
Doubs Cancer Registry, France.
21
Finistère Digestive Tract Registry, France.
22
Gironde CNS Tumour Registry, France.
23
Gironde Haematological Malignancies, France.
24
Hérault Cancer Registry, France.
25
Isère Cancer Registry, France.
26
Loire-Atlantique/Vendée Cancer Registry, France.
27
Manche Cancer Registry, France.
28
Marne & Ardennes, Thyroid, France.
29
Somme Cancer Registry, France.
30
Tarn Cancer Registry, France.
31
Berlin; Brandenburg; Mecklenburg-West Pomerania; Saxony; Saxony-Anhalt; Thüringen Cancer Registry, Germany.
32
Bremen Cancer Registry, Leibniz Institute for Prevention Research and Epidemiology, Germany.
33
Hamburg Cancer Registry, Germany.
34
Munich Cancer Registry, Germany.
35
North Rhine-Westphalia Cancer Registry, Germany.
36
Saarland Cancer Registry, Germany.
37
Icelandic Cancer Registry, Iceland.
38
National Cancer Registry Ireland, Ireland.
39
Alto Adige Cancer Registry, Italy.
40
Biella Cancer Registry, Italy.
41
Catanzaro Cancer Registry, Italy.
42
Firenze-Prato Cancer Registry, Italy.
43
Friuli Venezia Giulia, CRO Aviano National Cancer Institute, Italy.
44
Istituto Superiore di Sanità, Rome, Italy.
45
Latina Cancer Registry, Italy.
46
Liguria Mesothelioma Registry, Italy.
47
Mantova Cancer Registry, Italy.
48
Milano Cancer Registry, Italy.
49
Modena Cancer Registry, Italy.
50
Napoli 3 South Cancer Registry, Italy.
51
Nuoro Cancer Registry, Italy.
52
Palermo Cancer Registry, Italy.
53
Parma Cancer Registry, Italy.
54
Ragusa Cancer Registry, Italy.
55
Reggio Emilia Cancer Registry, Italy.
56
Romagna Cancer Registry, Italy.
57
RT Ferrara Cancer Registry, Italy.
58
RTR Liguria, IRCCS AOU SM-IST, Italy.
59
Salerno Cancer Registry, Italy.
60
Sassari Cancer Registry, Italy.
61
Servizio Epidemiologia Clinica e Valutativa, Trento, Italy.
62
Siracusa Cancer Registry, Italy.
63
Sondrio Cancer Registry, Italy.
64
Trapani Cancer Registry, Italy.
65
Umbria Cancer Registry, Italy.
66
Varese Province Cancer Registry, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy.
67
Veneto Cancer Registry, Italy.
68
Fondazione IRCCS, National Cancer Institute, Milan, Italy.
69
Latvian Cancer Registry, France.
70
Lithuaian Cancer Registry, France.
71
Malta National Cancer Registry, Health Information and Research, France.
72
Norwegian Cancer Registry, France.
73
Cracow Cancer Registry, Czech Republic.
74
Kielce Cancer Registry, Czech Republic.
75
Lower Silesia (Wroclaw) Cancer Registry, Czech Republic.
76
Açores Cancer Registry, Portugal.
77
Northern Portugal Cancer Registry, Portugal.
78
Southern Portugal Cancer Registry, Portugal.
79
Slovakian National Cancer Registry, Czech Republic.
80
Albacete. Castilla-La Mancha Cancer Registry, Spain.
81
Basque Country Cancer Registry, Spain.
82
Castellón-Valencia (breast) Cancer Registry, Spain.
83
Cuenca Cancer Registry, Spain.
84
Girona Cancer Registry, Spain.
85
Granada Cancer Registry CIBERESP, ibs.Granada, Spain.
86
Murcia Cancer Registry, CIBERESP, IMIB-Arrixaca, Spain.
87
Navarra Cancer Registry, CIBERESP, Spain.
88
Tarragona Cancer Registry, Spain.
89
Basel Cancer Registry, Switzerland.
90
Geneva Cancer Registry, Switzerland.
91
Grisons-Glarus, St. Gallen Cancer Registry, Switzerland.
92
Ticino Cancer Registry, Switzerland.
93
Valais Cancer Registry, Switzerland.
94
Public Health England, UK.
95
Northern Ireland Cancer Registry, Ireland.
96
Scotland Cancer Registry, UK.
97
Welsh Cancer Intelligence and Surveillance Unit, UK.
98
The Netherlands Cancer Registry, The Netherlands.
99
National Institute of Public Health-NIH, Warszawa, Czech Republic.
100
Cancer Registry of Republic of Slovenia, Slovenia.
101
Edinburgh Cancer Centre, University of Edinburgh, UK.
102
Institut de Cancérologie Gustave Roussy, Villejuif, France.

Abstract

Head and neck cancer (HNC) is a rare disease that can affect different sites and is characterized by variable incidence and 5-year survival rates across Europe. Multiple factors need to be considered when choosing the most appropriate treatment for HNC patients, such as age, comorbidities, social issues, and especially whether to prefer surgery or radiation-based protocols. Given the complexity of this scenario, the creation of a highly specialized multidisciplinary team is recommended to guarantee the best oncological outcome and prevent or adequately treat any adverse effect. Data from literature suggest that the multidisciplinary team-based approach is beneficial for HNC patients and lead to improved survival rates. This result is likely due to improved diagnostic and staging accuracy, a more efficacious therapeutic approach and enhanced communication across disciplines. Despite the benefit of MTD, it must be noted that this approach requires considerable time, effort and financial resources and is usually more frequent in highly organized and high-volume centers. Literature data on clinical research suggest that patients treated in high-accrual centers report better treatment outcomes compared to patients treated in low-volume centers, where a lower radiotherapy-compliance and worst overall survival have been reported. There is general agreement that treatment of rare cancers such as HNC should be concentrated in high volume, specialized and multidisciplinary centers. In order to achieve this goal, the creation of international collaboration network is fundamental. The European Reference Networks for example aim to create an international virtual advisory board, whose objectives are the exchange of expertise, training, clinical collaboration and the reduction of disparities and enhancement of rationalize migration across Europe. The purpose of our work is to review all aspects and challenges in and outside this network setting planned for the management of HNC patients.

KEYWORDS:

European reference networks joint action of rare cancers; Head and neck cancer; Multidisciplinary team; Rare disease

PMID:
29478741
DOI:
10.1016/j.ejso.2018.02.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center